CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL

Phase I clinical trial of EG12014 for treating breast cancer and stomach cancer was a success. The study was conducted in Europe and showed that EG12014 had met its primary endpoint of producing a pharmacokinetics profile that is comparable to Herceptin.

EG12014 is a biosimilar of trastuzumab, which is Roche's monoclonal antibody with brand name called Herceptin. A biosimilar drug is a near-identical copy of an original biologics and a different company can manufacture it after the expiration of the original biologics' patent.

Eirgenix has begun preparations for a phase III clinical trial which would be conducted in the US and European nations. The outcome paves the way for new opportunities for lower-priced biosimilar drugs as patents on mainstream oncology drugs approach their expiration dates in the next few years.